CDKN2B‐AS1, an lncRNA first identified in 2011, serves as a prognostic indicator and biomarker of the tumour immune microenvironment in thyroid and endometrial cancers [30, 31]. This evidence concerns the gene CDKN2B and endometrial cancer.